Navigation Links
Bionovo Announces 2007 Financial Results and Highlights
Date:3/13/2008

- 15,000

Other current liabilities 949,200 119,092

Total current liabilities 2,716,631 1,087,726

Non-current portion of lease obligation 526,346 300,741

Non-current portion of deferred revenue - 87,500

Commitments and contingencies

Shareholders' equity:

Common stock, $0.0001 par value, 190,000,000

shares authorized; issued and outstanding shares:

66,036,435 at December 31, 2007; 51,337,224

at December 31, 2006. 8,166 5,134

Additional paid-in capital 57,659,513 13,340,163

Accumulated other comprehensive income 4,480 -

Accumulated deficit (22,749,965) (9,848,967)

Total shareholders' equity 34,922,194 3,496,330

Total liabilities and shareholders' equity $38,165,171 $4,972,297

* The balance sheets at December 31, 2007 and 2006 has been derived from

the audited financial statements at that date but does not include all

of the information and footnotes required by accounting principles

generally accepted in the United States for complete financial


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Bionovo Announces Closing of Public Offering of Common Stock
2. Bionovo Describes a New Class of Therapeutic Compounds
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...Coach Holly Warlick Teams Up with Legal and Medica...Ever Cancer and Careers Seminar in,Knoxville, KNO...ion of National,Breast Cancer Awareness Month, Can...e joined forces with YWCA Knoxville, The Wellness ...e Holly Warlick, University of Tennessee,women,s b...
(Date:10/10/2008)... The Healthcare Technology Ev... , Exton, PA (PRWEB) Sept...ey Chapters of the national Healthcare Information...forces to bring regional health information techno... conference entitled The Healthcare Technology Evo...
(Date:10/10/2008)...ston, MABoston Medical Center (BMC) has received a...l Institute on Aging (NIA) to fund the Boston Clau...BMC,s Pepper Center is one of only 11 Pepper Cente... Americans Independence Center Program was establi...enator from Florida. During his five decades of pu...
(Date:10/10/2008)...olecular CT adds metabolic information from PET to...gnostic imaging for maximized workflow ...ICH, Germany, Oct. 10 /PRNewswire/ -- Siemens Heal...duces molecular CT, a new concept in,integrated im...d is a,practical solution for today,s shrinking he...
Breaking Medicine News(10 mins):Health News:Local Experts Help Women Living and Working with Cancer Even the Score 2Health News:Local Experts Help Women Living and Working with Cancer Even the Score 3Health News:Local Experts Help Women Living and Working with Cancer Even the Score 4Health News:HIMSS New Jersey and Delaware Valley Chapters Sponsor Regional Conference 2Health News:Boston Medical Center receives $5.8m grant 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 2Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 3Health News:Siemens Shapes the Future of Integrated Diagnostic Imaging 4
...ad entered a co-development and commercialisation ...he joint development of a drug to treat diabetes. ...ts associated with the Phase-III clinical trials o...PPAR-gamma agonist, for the treatment of type 2 di...
...opical Medicine has published the results of the w...hat the HIV virus has become less pathogenic// due...nsitive to anti-retroviral drugs compared to the s... compared the HIV samples collected in between 198...
...y not require blood transfusion as a treatment pro...form of severe thalassaemia in many Asian// countr...ients, suggests a research letter published online... The authors state that the finding has important ...
...r on the body, says a new study that offers hope f...es at Johns Hopkins University School// of Medicin...ich encodes a protein that is essential for hair f...umans and mice with mutations in the Hairless gene...
Other Medicine News:Health News:Dr Reddy’s Strikes Deal With Rheoscience For Type 2 Diabetes Dru 2
(Date:10/10/2008)...lif., Oct. 10 /- TriReme Medical Inc.... to affix the CE (Conformite,Europeenne) marking a...y,Stent System, a unique main vessel stent system ...urcations., Representing the next generation in b...tential use in a quarter of the 2.2 million,angiop...
(Date:10/9/2008)...cal Results Expected in November 2008, BOTHELL, W...a, Inc.,(Amex: DDD ) announced today the completi...of its three pivotal trials to evaluate the safety...ed-release (ER) ibuprofen for,the over-the-counter...ine,results from this pivotal trial in November 20...
(Date:10/8/2008)...l Reduce Animal Use in Cosmetics and Chemicals Tes...ek Corp. today announced,that results of a recentl...h-up" validation study on MatTek,s EpiDerm in vitr...emonstrated the required sensitivity and,specifici...native to animal,testing for determining human ski...
(Date:10/8/2008)...ersity Food Scientists Expand Testing Using Cellul...y, PORTLAND, Maine, Oct. 8 /- Wild B...the release of results from a new study,showing Wi... consumed,fruits like apples, bananas, red grapes ...lular Antioxidant Activity (CAA) assay. New resear...
Breaking Medicine Technology:TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference 3593 1Microchip Biotechnologies Inc Collaborating With Stanford University on Developing a Front End Microfluidic Based Sample Preparation System for Pyro 3591 1Microchip Biotechnologies Inc Collaborating With Stanford University on Developing a Front End Microfluidic Based Sample Preparation System for Pyro 3591 2New genetic association with schizophrenia found by researchers 13000 1New genetic association with schizophrenia found by researchers 13000 2iCAD Introduces Next Generation TotalLook Film Digitizer 12996 1iCAD Introduces Next Generation TotalLook Film Digitizer 12996 2iCAD Introduces Next Generation TotalLook Film Digitizer 12996 3
...07 /PRNewswire-FirstCall/ -- CEL-SCI,CORPORATION a...se,against H5 avian influenza antigen in combinati...stem. These findings were,presented on May 23, 200...f Research, Cellular Immunology at CEL-SCI at the,...eneral meeting in,Toronto, Canada. , This new find...
... /PRNewswire-FirstCall/ -- Shire plc,announced tha...),the first and only non-oral medication approved...Disorder (ADHD) in children aged 6,to 12 years, pr...and tolerability, according to results of a 12-mon...hiatric Association (APA),annual meeting in San Di...
Other Medicine Technology:CEL-SCI'S CEL-1000 Shown to Significantly Enhance Immune Response,Against Avian Flu Antigen in Animals 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 212-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 312-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 412-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 512-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 612-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 712-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 812-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA,(methylphenidate transdermal system) 9
Agarose I (Molecular Biology Grade) - A regular melting temperature agarose for electrophoresis requiring an exceptional level of purity with unequaled performance.
UltraClean Agarose, Molecular Biology Grade, is used for the electrophoretic separation of nucleic acids. It can be used to isolate DNA fragments from 0.2 to 40 kb., Each lot of UltraClean Agarose is
Inquire
High EEO (-mr) (0.23-0.26), suitable for IEP, Gel point (1.5%): 36 1.5 °C Gel strength (1%): > 750 g/cm2.
Medicine Products: